Related Experiment Videos
Carboplatin-induced immune hemolytic anemia
T M Marani1, M B Trich, K S Armstrong
1Clinical Services, American Red Cross Blood Services, Greater Chesapeake and Potomac Region, Baltimore, Maryland, USA.
Transfusion
|November 1, 1996
Summary
Carboplatin, an anticancer drug, can cause acute hemolysis due to a carboplatin-induced antibody. This previously unreported complication involves immune complex, drug adsorption, and autoantibody mechanisms, highlighting a potential risk in chemotherapy.
Area of Science:
- Oncology
- Hematology
- Immunology
Background:
- Carboplatin is an anticancer chemotherapeutic agent.
- Hemolytic anemia is a known side effect of cisplatin, a related drug, but not previously reported for carboplatin.
Observation:
- An 8-year-old boy treated with carboplatin for astrocytoma developed lower back pain after 26 injections.
- Overt intravascular hemolysis occurred after the 27th carboplatin injection, confirmed by a positive direct antiglobulin test.
Findings:
- Testing revealed carboplatin-dependent antibodies in the patient's blood.
- The patient's serum showed a positive indirect antiglobulin test in the presence of carboplatin, indicating a drug-dependent antibody response.
- Antibody titers were significantly elevated in the presence of carboplatin, confirming its role in the hemolytic reaction.
Implications:
- This case suggests carboplatin can induce drug-dependent hemolysis through a complex antibody mechanism.
- Drug-dependent hemolysis is a potentially serious, previously unreported complication of carboplatin therapy.
- Awareness of this adverse reaction is crucial for monitoring patients undergoing carboplatin treatment.